FDA defends costly Singapore conference attendance amid budget cuts and public scrutiny
A luxury resort setting, a prolonged U.S. government shutdown, and a federal agency under pressure converged in Singapore, raising sharp questions about priorities, spending, and public trust.
Costly Travel Amid a Historic Shutdown
In mid-November, 31 staff members from the U.S. Food and Drug Administration traveled to Sentosa Island, Singapore, to attend a conference organized by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or ICH. Internal FDA records obtained by CNBC show the trip cost more than $250,000, averaging over $8,000 per person. The timing was sensitive, as the travel occurred in the final days of the longest U.S. government shutdown in history, which lasted 43 days.
Pressure on a Strained Agency
The trip unfolded as the FDA faced mounting internal challenges. The Trump administration proposed an 11.5 percent cut to the agency’s budget, while nearly 1,900 staff members were laid off and about 1,200 accepted early retirement packages, according to testimony by FDA Commissioner Marty Makary in May. Leadership instability and public criticism over vaccine and regulatory policies further intensified scrutiny of the agency’s decisions.
Why Singapore Mattered
The ICH conference, held on Nov. 18 and 19 at the Sentosa resort, brought together approximately 500 regulators and pharmaceutical experts from around the world. The ICH, a nonprofit registered under Swiss law, aims to harmonize global drug development and approval standards. During the meeting, three major guidelines were adopted to standardize clinical trial protocols, improve post-approval safety reporting, and establish international standards for real-world data studies. FDA representatives contributed to all three, reinforcing the agency’s role as a founding member of ICH.
FDA’s Defense of the Trip
The FDA told CNBC that attendance was mission critical and essential to supporting global alignment on drug development, regulatory science, and patient safety. The agency emphasized that the trip was funded through carryover user fees collected from pharmaceutical and medical device companies, not direct taxpayer funds. Approval for the travel reportedly came from senior leadership, including Chief Operating Officer Barclay Butler, with attendance reduced to 31 staff members compared to nearly 50 in previous years.
Optics and Accountability Concerns
Despite these explanations, watchdog groups questioned the optics of international travel during a shutdown. Dylan Hedtler-Gaudette of the Project On Government Oversight said the decision raised concerns about priorities, even if the conference itself was valuable. He argued that user fees are still public funds and should be treated with the same level of care as taxpayer dollars, especially during periods of reduced government operations.
Internal Doubts and Policy Shifts
Internal FDA emails reviewed by CNBC reveal unease within the agency itself. Some senior officials proposed canceling in-person conference travel during the funding lapse and limiting participation to virtual appearances. FDA documents also acknowledged that travel during a shutdown could be poorly received. Notably, guidance on shutdown-era travel approvals was removed from the agency’s website shortly after media inquiries.
The FDA’s Singapore trip highlights a broader dilemma facing global regulators: balancing international collaboration with fiscal restraint and public perception. For Indonesians and Singaporeans observing regulatory cooperation in the region, the episode underscores both Singapore’s role as a global policy hub and the growing demand for transparency when public institutions operate under financial and political strain.
Sources: CNBC (2025)
Keywords: FDA Travel, Singapore Conference, Government Shutdown, Drug Safety Standards, Public Accountability
